S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Sarepta Therapeutics Price Target, Predictions & Analyst Ratings

-1.82 (-2.05 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $87.11
50-Day Range
MA: $90.79
52-Week Range
Now: $87.11
Volume1.25 million shs
Average Volume2.70 million shs
Market Capitalization$6.87 billion
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Sarepta Therapeutics (NASDAQ:SRPT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
22 Wall Street analysts have issued ratings and price targets for Sarepta Therapeutics in the last 12 months. Their average twelve-month price target is $150.48, predicting that the stock has a possible upside of 72.74%. The high price target for SRPT is $230.00 and the low price target for SRPT is $73.00. There are currently 1 sell rating, 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
SRPT Consensus Rating: BuyBuyBuyBuy
SRPT Consensus Rating Score: 2.502.582.882.92
SRPT Analyst Ratings: 1 Sell Rating(s)
9 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
22 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
22 Buy Rating(s)
0 Strong Buy Rating(s)
SRPT Consensus Price Target: $150.48$161.96$195.67$197.30
SRPT Price Target Upside: 72.74% upside9.30% upside45.50% upside49.93% upside

Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021Royal Bank of CanadaLower Price TargetOutperform$143.00 ➝ $132.00High
3/2/2021Needham & Company LLCReiterated RatingBuy$166.00High
3/2/2021SVB LeerinkBoost Price TargetOutperform$125.00 ➝ $126.00High
3/2/2021Piper SandlerLower Price TargetNeutral$140.00 ➝ $130.00High
2/26/2021MizuhoBoost Price TargetBuy$158.00 ➝ $160.00High
1/12/2021Smith Barney CitigroupDowngradeBuy ➝ NeutralHigh
1/12/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy ➝ Neutral$215.00 ➝ $108.00Medium
1/11/2021UBS GroupDowngradeBuy ➝ NeutralHigh
1/8/2021OppenheimerReiterated RatingHold ➝ NeutralHigh
1/8/2021Credit Suisse GroupLower Price TargetNeutral$156.00 ➝ $73.00N/A
1/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$96.00N/A
1/8/2021Robert W. BairdLower Price TargetOutperform$223.00 ➝ $110.00N/A
1/8/2021CowenLower Price TargetOutperform$213.00 ➝ $114.00N/A
1/8/2021BarclaysLower Price TargetPositive ➝ Overweight$192.00 ➝ $125.00N/A
1/8/2021Cantor FitzgeraldLower Price TargetOverweight$217.00 ➝ $128.00N/A
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$182.00 ➝ $95.00N/A
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
11/11/2020Berenberg BankInitiated CoverageHold$140.00Medium
8/31/2020HC WainwrightLower Price TargetBuy$260.00 ➝ $221.00Low
8/21/2020Bank of AmericaLower Price TargetBuy$190.00 ➝ $189.00Medium
5/17/2020NomuraReiterated RatingBuy$230.00High
2/27/2020JMP SecuritiesLower Price TargetOutperform$280.00 ➝ $217.00High
2/25/2020Nomura SecuritiesReiterated RatingBuy$230.00High
12/24/2019The Goldman Sachs GroupReiterated RatingBuy$180.00Low
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$210.00N/A
12/13/2019Janney Montgomery ScottBoost Price TargetBuy$160.00 ➝ $175.00High
11/1/2019GuggenheimInitiated CoverageBuy$183.00High
8/9/2019William BlairReiterated RatingBuyLow
8/8/2019Evercore ISIReiterated RatingBuy$200.00High
4/17/2019BTIG ResearchSet Price TargetBuy$190.00High
3/12/2019BMO Capital MarketsInitiated CoverageOutperformLow
10/12/2018Sanford C. BernsteinInitiated CoverageOutperform$170.00High
6/22/2018SunTrust BanksBoost Price TargetBuy$176.00High
6/20/2018WBB SecuritiesReiterated RatingBuyLow
(Data available from 3/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.